Gene Therapy VY-AADC Improves Motor Function in Parkinson’s Patients, Studies Show

One-time treatment with investigational gene therapy VY-AADC (NBIb-1817) showed sustained improvement in motor function in patients with Parkinson’s, results from the Phase 1 PD-1102 clinical trial show. These results were presented recently in two poster presentations at the MDS Virtual Congress 2020. VY-AADC, a gene therapy being…

Gene Therapy Seen to Raise Response to Levodopa Given as IV Infusion in Trial

An investigational gene therapy, called VY‐AADC01, boosts motor responses to levodopa that is given intravenously —particularly at a low dose — in people with Parkinson’s disease, a sub-study within a Phase 1b trial shows. These findings, along with positive data from the main PD-1101 study (NCT01973543), support the potential…